IntegraDose Compounding Services, LLC, Shoreview, MN

Is IntegraDose Compounding Services, LLC registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names IntegraDose Compounding Services, LLC in Shoreview, MN, first registered Feb 13, 2026 and most recently registered Oct 7, 2026.

Does IntegraDose Compounding Services, LLC hold a Minnesota pharmacy license?

State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

Has IntegraDose Compounding Services, LLC had a state board action or FDA letter?

FDA letters: no matching record found. No entry for IntegraDose Compounding Services, LLC was matched by name and location on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026. The page does list IntegraDose Compounding Services, LLC in Minneapolis, MN, a close but not exact match shown below. State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
IntegraDose Compounding Services, LLC
Location
Shoreview, MN
Type as FDA labels it
503B
FDA 503B list
Listed as IntegraDose Compounding Services, LLC
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
None listed
FDA Data Dashboard inspections
4 inspections: 3 OAI, 1 VAI; 5 published Form 483s
Form 483 text on this page
4 Form 483s, 22 observations
State board records
Not checked

FDA inspections and letters

No entry for this name and location was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). That page covers actions from 2019 on; FDA keeps earlier ones in its archive.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists IntegraDose Compounding Services LLC, Shoreview, MN (FEI number 3014483112), matched to this page by exact name, city and state. It lists 4 inspections: 3 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jul 25, 2025Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30144831121276828
Mar 1, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30144831121231700
Aug 2, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30144831121147614
Sep 19, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30144831121066036

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 22 numbered observations in all, across 4 inspections ending Sep 19, 2018 to Aug 12, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 4, 2026 to Aug 12, 2026: 4 observations

Firm on the cover
IntegraDose Compounding Services LLC, 3650 Victoria St N Ste 900, Shoreview, MN 55126-2906
FEI number
3014483112
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
250 Marquette Ave, Ste. 600 Minneapolis, MN 55401
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

Specifically,

A.

Your cleanroom certification conducted on June 29, 2026, and June 30, 2026, shows that HEPA Filter <Redacted B4> in Production Room <Redacted B4> (ISO 7 ) did not pass airflow and <Redacted B4> as the report states the result as N/A and notes "HEPA Filter 8 in need of motor replacement." Your firm produced <Redacted B4> batches of drug products in Production Room <Redacted B4> between June 30, 2026, and August 4, 2026, <Redacted B4> of which have been distributed. No investigation or CAPA has been opened to assess the impact of this specific HEPA Filter on your operations.

B.

During the inspection walk through of your classified spaces on August 7, 2026, it was observed that HEPA filters in your ISO 7 production areas are equipped with indicator lights. ...

Read the full 483 (PDF on fda.gov)

Observation 2

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

A.

Your firm qualifies visual inspectors and AQL inspectors on <Redacted B4> basis. The following deficiencies in inspector qualification were identified during the inspection:

Following the start of operations at your new facility on February 2, 2026, your firm did not perform requalification of visual inspectors or AQL inspectors for the new facility. Instead, your firm continued to use qualifications performed at your previous facility. No assessment or justification for carrying over previous facility qualifications to the new facility was identified during the inspection. Visual inspection qualification is specific to the environment and equipment under which it is performed and qualifications conducted at a previous facility cannot be assumed to remain valid under the different conditions of a new facility.

In May 2026, your firm introduced <Redacted B4> new visual inspection booths in a new visual inspection room at your current facility. Your firm did not perform requalification of visual inspectors for these new booths prior to their use. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically,

Smoke studies conducted on December 31, 2025, did not adequately reflect observed production operations. On August 5, 2026, video recordings of the production of Hydromorphone HCL 20mg/100mL CADDS lot #20260720HYD-1 , EXP November 17, 2026, completed on <Redacted B4>, were reviewed. The following discrepancies were observed in the smoke study videos:

1. The batch video, during production, showed <Redacted B4> operators performing individual tasks in each ISO 5 Laminar Airflow Hood (LAFH). The smoke studies only demonstrated one operator individually performing one task in each video.

2. The smoke study for the CADDs products shows the CADDs lined up with about 2 -3 inches of space between the CADD and the back wall of the <Redacted B4> airflow LAFH. During the batch video the CADDs were observed to be placed directly in front of the back wall with no gap. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

On August 5, 2026, video recordings of the production of Hydromorphone HCL 20mg/100mL CADDS lot #20260720HYD-l, EXP November 17, 2026, completed <Redacted B4> were reviewed. During this video review the following was observed:

Your production operators were observed placing the settle plates in the comers of the LAFHs before the start of the batch. Your SOP-0015 Environmental Monitoring (EM) Program: 503B Cleanroom, states placement should be", <Redacted B4> from the back/HEPA filter."

Your firm does not document the time post production EM samples are taken.

Inspection Feb 12, 2024 to Mar 1, 2024: 8 observations

Firm on the cover
IntegraDose Compounding Services LLC, 719 Kasota Ave Se, Minneapolis, MN 55414 -2842
FEI number
3014483112
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
250 Marquette Ave, Ste. 600 Minneapolis, MN 55401
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

There is a failure to thoroughly review any unexplained discrepancy and the failure ofa batch or any of its components to meet any of its specifications whether or not the batch has been ah-eady distributed.

Specifically,

a) Your firm invalidated a positive sterility test result without a root cause identified for Cefazolin 2 Gram/20 ML Syringe for Injection, Batch# <Redacted B4>, manufacturing date (MFG): 07/20/2022. Your contract testing laboratory stated they could not invalidate their result based on your response and their findings. Your investigation resulted in a batch rejection, but you failed to identify the root cause for the positive sterility test result and your firm did not implement any corrective actions within your facility in response to the test results.

b) During your firm's visual inspection of Cefazolin 3 Gram/30 mL in Sterile Water Syringe fo r Injection (Batch <Redact ed B4> MFG: 09/26/2022]), you initially identified 45 leaking syring es. During your re-inspect ion vou found 20 additional leaking syringes. There were 65 total lea ki. syringes for Batch# < Reda cted B4> classified as critical defect units out of an actual y ield of syringes for the batch. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

*Repeat observation from FDA inspections ending on 09/19/2018 and 08/02/2021 *

a) Dynamic smoke studies performed in the ISO-5 hoods are not representative of conditions observed during production. We observed the production of Fentanyl Citrate 400 mcg/200 mL + Ropivacaine HCl 200 mg/200 mL in 0.9% Sodium Chloride, CADD for Injection on 02/13/2024 (Batch# <Redacted B4> and reviewed video of production on 01/23/2024 (Batch# <Redacted B4> MFG: 01 2372'""'0~2:•4---Your firm has only conducted dynamic smoke studies on smaller cassettes (50 mL) compared to the larger cassettes (200 mL) observed. We observed that the production process had far more obstructions to airflow in the ISO-5 hood with stacked container closures stems than you challenged in the dynamic smoke studies of the small cassettes. Batch# <Redacted B4> was released by your Quality Unit on 02/05/2024. b) Your firm does not have a dedicated garbing area for cleanroom operations. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically,

*Repeat observation from FDA inspection ending 08/02/2021 *

a) Your firm only monitors non-viable particles in your ISO-5 hoods for production on <Redac ted B4> ba

sis. b) Your firm only monitors active viable air within your ISO-5 hoods for produc

tion on <Redacted B4> basis. c) We observed the following during our review of your firm's dynamic smoke studies; i) Adequate smoke is not being used to assess airflow during all dynamic operations. Additionally, angle of certain smoke study videos prevent proper assessment of airflow. ii) Components in the hood are touching the back HEPA filter grate. iii) Movements by the operator during the smoke study are fast and turbulent.

angles ofcertain smoke study videos prevent proper assessment of airflow. ii) Components in the hood are touching the back HEP A filter grate. iii) Movements by the operator during the smoke study are fast and turbulent.

Observation for the Production System

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

*Repeat observation from FDA inspection ending 08/02/2021 *

a) We reviewed video of~ leaning within room-performed on 01/1 9/2024, as well as in <Redacted B4> performed on 01/12/2024. Your cleanings of the walls and ceilings are conducted by an external contractor. The following was observed: i) The cleaner only submerses the mop once outside of the ISO-7 room to fully clean the entirety of the walls. This was observed in both <Redaceted B4> and <Redacted B4>and-. ii) The cleaner did not move the large utility cart to clean the wall behind it in both production suites in both <Redacted B4> and <Redacted B4> . iii) Whi e sticky rolling the floor in <Redacted B4>, the cleaner only sticky rolled half of the floor. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

Your firm has not performed process validation for your drug products. You have made the following products since Summer 2022:

We reviewed the current status of your ongoing recall (D-0258-2024) for Vasopressin 2 Units / 2 mL in 0.9% Sodium Chloride which includes nine sub-potent batches within your 180-day BUD that failed from 67 to I 09 days after production. All of these sub-potent batches were the initial batches of a process change from using a <Redacted B4> pump (100 syringe units) to a repeater pump (400 syringe units). Your firm's change request 01m on y states that "Change in process is minor but requires review of updated process training for production staff' for this process change. The root cause of your recall investigation is still ongoing.

Observation for the Production System

Observation 6

The control systems necessary to prevent contamination or mix-ups are deficient.

Specifically,

a) Your firm lacks a risk assessment / mitigation strategy for spills of non-penicillin beta-lactam liquid (cefazolin) within your ISO-5 compounding hood in suite ). Your firm's spill clean-up procedure is non-specific to the type of spill and contains no mention of a deactivating agent. b) During our visual inspection of finished product on 2/16/2024, we found unidentified white particulate matter on the outside of syringes near the needle point of Cefazolin 3 Gram/30 mL, Syringe for Injection (Batch# <Redacted B4> 202401 26CE11!1[MFG ]) and Cefazolin 2 Gram/20 mL, Syringe for Injection (Lot# 202401 IOCEII [MFG: . these two batches were released. c) We reviewed video of visual inspections of cefazolin syringes conducted on 02/12/2024. Your firm isn't properly using per your training and visual inspection protocol. The visual inspectors are trame 1 erent and what is conducted during production visual inspection. We observed during video review that the inspectors are either not using <Redacted B4> since they are <Redacted B4> or is nearly fully obstructed by syringes on it. ...

Read the full 483 (PDF on fda.gov)

Observation 7

The quality control unit lacks responsibility to approve all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically,

Observation 8

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.

Specifically,

The following products were compounded but were not reported in your December 2023 product report a) Bupivacaine HCl 0.25% +Epinephrine 1:200,000, 30 mL Vial for Injection b) Bupivacaine HCl 0.5% + Epinephrine I :200,000, 30 mL Vial for Injection

Inspection Jul 12, 2021 to Aug 2, 2021: 4 observations

Firm on the cover
IntegraDose Compounding Services LLC, 719 Kasota Ave Se, Minneapolis, MN 55414 -2842
FEI number
3014483112
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
250 Marquette Ave, Ste. 600 Minneapolis, MN 55401
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Individual media fills performed by personnel are limited to units and not representative of production quantities and process. For example, Lot <Redacted B4>, produced on 7/12/2021, filled and capped approximately <Redacted B4> syringes of drug product using a repeater pump. h

Specifically,

-On 6/28/21, the <Redacted B4> cleaning was not performed due to an HVAC Discrepancy and later that day production was performed for Cefazolin Lot #'s <Redacted B4>. These lots were approved for Final Release by Quality on 7/20/21 . This HVAC event was not recorded in the Cleanroom Event Log, therefore not reviewed by the quality unit.

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

-On 7/19/21, we observed a video from 7/1/21 from room <Redacted B4>, an ISO 7 Cleanroom, where a square on the floor was missed in mopping. Furthermore, in room <Redacted B4>, an ISO 7 Cleanroom, a mop head was used for two squares instead of being changed after each square, as stated in the Cleaning SOP EV-5010 Cleaning Program: 503B Cleamoom Rev. 02 Effective 8/17/20. During these same cleanings, a worker touched the bottom of the dirty mop head with their gloved hand while changing the mop head and did not change gloves nor sanitize gloves, and subsequently touched cart handles, chairs and door handles. The cleaners also used a back-and-forth mopping pattern while mopping the floor as opposed to a figure-8 pattern.

-On 7/19/21 we observed a worker on 7/1/21 spray <Redacted B4> detergent and <Redacted B4> for disinfecting on a stainless-steel cart and not wait the designated dwell time to remove the product as stated in the Cleaning SOP EV-5010 Cleaning Program: 503B Cleanroom Rev. 02 Effective 8/17/20. ...

Read the full 483 (PDF on fda.gov)

Observation 3

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

Approximately 100 Events and 20 CAPA's from 2019-2021 are open past the completion due date deadline as defined in SOP PQ-5075.1 "Corrective and Preventative Action (CAPA) Management'' Eff. 12/2018 and PQ-5245 "Event Investigations" Eff. 12/2018.

For example:

1) EV-0396 "Cefazolin hood <Redacted B4> pressure 0, power failure during <Redacted B4> " Date of Occurence: 03/30/2020

2) EV-0961 "Personnel EM (forehead) > action limit w/ 35 CFUs;, <Redacted B4> " Date of OccmTence: 04/05/2021

Quality fails to transfer all hand-written events from batch records to their internal event log. For example, batch record <Redacted B4> contains a hand-written note "Particle counter unable to obtain <Redacted B4> reading after <Redacted B4> runs. Re-cleaned <Redacted B4> and obtained <Redacted B4> reading <Redacted B4> 06/29/21. This event was not transferred to their Internal event log. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically,

-Dynamic smoke studies performed in the ISO-5 hoods were not representative of conditions I observed during production. The smoke study performed only included <Redacted B4>. On 7/12/21 during production of Lot <Redacted B4> up to 10 boxes of syringes, multiple packages of caps, two IV bags, and a balance were observed inside the ISO-5 processing area.

-After installation of a new <Redacted B4> Hood located in ISO 7 room <Redacted B4> on 4/10/21 a smoke study was not performed. This hood is currently in use for Cefazolin production and was used in producing multiple lots including Lot <Redacted B4> 4

-On 7/20/2021 we observed video of the cleaning performed of an ISO-7 room <Redacted B4> on 7/2/2021 where the cleaning crew moved the ISO 5 LAF Hoods to clean behind them. Your firm verbally stated that the hoods are moved <Redacted B4> for routine cleaning. Your firm fails to re-qualify hoods each time they are moved for cleaning.

Inspection Sep 10, 2018 to Sep 19, 2018: 6 observations

Firm on the cover
, 719 Kasota Ave Se IntegraDose Compounding Services LLC, Minneapolis, MN 55414 - 2842
FEI number
3014483112
Establishment type on the cover
503B Outsourcing Facility
FDA district office on the cover
300 River Place, Suite 5900 Detroit, MI 48207
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Your firm received the following out-of-specification results for release testing and did not identify a laboratory error or root cause, and released product based solely on retesting.

For example:

Ephed1ine Sulfate 25mg/SmL in 0.9% Sodium Chloride Syringe for Injection Lot 20180228EPH-l , produced on 2/28/2018, received a "Positive <Redacted B4> result (specification "Negative at <Redacted B4> on 3/7/2018, which indicates possible microbiological contamination. This lot was released for distribution on 4/23/18 without adequate investigation into the sterility failure.

132.6% (specification[(of <Redacted B4> on 11/6/2017

135.9% (specification <Redacted B4> on 11/15/2017

136.7% (specification <Redacted B4> on 11/15/2017

This lot was released for distiibution on 11/27/2017.

Hydromorphone 0.5mg/0.5mL in 0.9% Sodium Chloride Syringe for Injection (Concentration lmg/mL) Lot 20171219HYD-l, produced on 12/19/2017, received the following potency results: ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

(A) Your firm does not conduct media fills or process simulations, at least <Redacted B4> for each operator, that also include: stressful/challenging conditions, all possible interventions and planned or unplanned), or simulations of the maximum number of persons allowed in the clean room. For example:

(1) Only <Redacted B4> media fill lot (out <Redacted B4> attempted since Febmaiy 2016), has been successfully completed and representative of syringe production conditions. The other syringe Media Fill failed, and thern <Redacted B4> Media Fill lots for IV bag production have either failed sterility testing or are not representative of production practices.

(2) Individual Media Fills performed by personnel are limited to <Redacted B4> isyringe units and not representative of production quantities. For example, Lot 20180115CEF-2, produceed on 1/15/2018, filled EJ IV bags of drug product. This lot was released for distiibution on 2/7/18.

(B) During production of Phenylephiine Hydrochloride, Lot 2018091 lPHE-2, produced on 9/1 1/2018, I ...

Read the full 483 (PDF on fda.gov)

Observation 3

Test devices are deficient in that instruments not meeting established specifications are used.

The "room-temperature" incubator, equipment <Redacted B4> , is not qualified for your intended use. This incubator was initially qualified on 1/27/2016 for incubating personal and surface samples collected as part of your environmental monitoring program. On November 17, 2017, your firm initiated an investigation of "ice buildup" in the incubator and concluded that the unit is functioning as expected but would require regular thawing/defrosting. Since November of 2017, no initial or ongoing operational or performance qualification was performed to ensure that, despite the presence office, this incubator could store environmental monitoring samples at optimum temperatures, per USP, to promote growth.

QUALITY SYSTEM

Observation 4

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

Procedure PQ5085 Deviation Management does not require a time line for the resolution of deviations. Additionally, this procedure states that "[b]ased on the event and severity of impact, the deviation report is closed or elevated to a CAP A for additional investigation along with connective and/or preventive actions. Approximately 37 Deviations from 2017 and 25 Deviations from 2018 remain open despite that your firm's QA manager has not elevated these deviations to a CAP A.

FACILITIIES AND EQUIPMENT SYSTEM

Observation 5

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically,

Smoke studies performed of the IS0-5 hoods were not representative of conditions observed during product.ion. Smoke studies consisted of <Redacted B4> operators slowly waving their hands, one of whom was not holding any equipment, for <Redacted B4> . Equipment such as large hanging IV bags, packaging, stoppers, vials, caps, and pumps were observed in <Redacted B4> the IS0-5 processing area during production of Lots 2018091 l PHE-2 on 9/11/2018 and 20180918FEN-1on 9/18/18.

Observation 6

There is a lack of written procedm es describing in sufficient detail the methods, equipment and materials to be used for sanitation.

Specifically,

During production of Phenylephline Hydrochloride, Lot 2018091 l PHE, on 9/11/2018, I observed the following:

• While wiping materials for entry into the ISO-7 space, a technician dropped a bottle of <Redacted B4> on the floor and used the same gloves to pick it up and continue wiping materials, without re-sanitizing her gloves or the bottle.

the bottle. • While cleaning the IS0-5 hoods in preparation for compounding, I observed a technician hang cleaning bottles on the sides of garbage can and repeatedly touch the garbage can in between wiping down the inside of the IS0-5 without sanitizing her hands.

Your firm's SOPs PQ-5050 Product Lifecycle; EV-5005.1 Cleanroom Entiy, Garbing, Hand Hygiene; or EQ­5065 .1 PECs -Hoods, Use and Cleaning do not describe how to handle cleaning products or items dropped on the floor during the material process steps, nor do these procedures desc1ibe where to store cleaning bottles inside the ISO-7 area while preparing the hoods for production.

State board of pharmacy records

State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

FDA’s 503B list

Close but not exact matches

These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.